CRISPR Therapeutics AG (CRSP) stock: key figures, P/E, revenue and dividend
Health Care · ISIN USH171821087
CRISPR Therapeutics AG financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 3.51 m USD |
| Operating income | -664.57 m USD |
| EBIT | -577.97 m USD |
| Net income | -581.60 m USD |
| Diluted EPS – continuing operations | -6.47 USD |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
More stocks
- AAK AB (publ) (AAK.ST)
- Shenzhen Sunlord Electronics Co Ltd (002138.SZ)
- ARGAN INC (AGX)
- Floor & Decor Holdings, Inc. (FND)
- Kurita Water Industries Ltd (6370.T)
- Aurizon Holdings Ltd (AZJ.AX)
- Hisense Kelon Electrical Holdings Co Ltd (000921.SZ)
- Asia Potash International Investment Guangzhou Co Ltd (000893.SZ)
- Virtu Financial, Inc. (VIRT)
- Blue Owl Capital Corp (OBDC)
- Acea SpA (ACE.MI)
- United Tractors Tbk PT (UNTR.JK)
Not investment advice. All data without warranty, price as of 21.10.2026. Details in the risk notice.